Navigation Links
Scientists decipher genome of fungus that can cause life-threatening infections

e first time on a genome-wide scale in fungi, examples of "alternative splicing" and "antisense" transcripts, in which the gene on one strand of the DNA differs from the counterpart gene on the opposite strand. Researchers also identified a high percentage of transposons (moveable elements) within the genome, which may account for the genome rearrangements often observed between different Cryptococcus isolates. TIGR's Fraser says the Cryptococcus genome sequence will benefit a wide range of biomedical research into the increasingly significant human pathogen. Stanford's Hyman says, "The two new Cryoptococcus genome sequences and their analysis provide many targets for vaccine development and drug discovery." Scientists in the C. neoformans research community - including Heitman at Duke and Jennifer Lodge at Saint Louis University (SLU) School of Medicine ?say the project already has given impetus to biomedical research into fungal infections. "The genome project has already had a major impact on basic research of Cryptococcus and will continue to be an enormous factor in the pace of discovery and in the scope of questions that can be asked about the basic biology of Cryptococcus as well as the disease process," says Lodge, who is SLU's Associate Dean for Research and who helped coordinate the C. neoformans genome project. Heitman says, "The genomic sequence and transcriptome analysis are already proving to be invaluable to researchers working to understand and cure this infectious disease." He says the genome sequence has enabled more rapid gene identification, fueled genome wide insertional mutagenesis approaches, and provided the foundation for the development and implementation of a genetic map for quantitative genetics and population analysis. In addition, the accuracy of the gene annotation makes it feasible to use Cryptococcus as a model to study how fungi cause disease. Using the genomic sequence data, the Cryptococcus research community already has designed
'"/>

Source:TIGR


Page: 1 2 3 4

Related biology news :

1. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
2. Scientists Replicate Hepatitis C Virus in Laboratory
3. Scientists detect probable genetic cause of some Parkinsons disease cases
4. Scientists find missing enzyme for tuberculosis iron scavenging pathway
5. Scientists seek answers on what activates deadly anthrax spores
6. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
7. Scientists collaborate to assess health of global environment
8. Scientists discover the cellular roots of graying hair
9. Scientists rid stem cell culture of key animal cells
10. Scientists develop new color-coded test for protein folding
11. Scientists identify genetic pathways essential to RNA interference

Post Your Comments:
(Date:12/2/2009)..., PHILADELPHIA New study results strengthen the ...ong period of time have an increased risk for deve... other risk factors. , "This provides one more ...e," said senior author Michael J. Thun, M.D., M.S....llance research at the American Cancer Society. "C...
(Date:12/2/2009)..., PHILADELPHIA Mexican-American adolescents expo... likely to pick up the habit themselves, and this ...d with smoking initiation, according to new study ...smoking in the United States and highlights the gl...on Framework Convention on Tobacco Control, which ...
(Date:12/2/2009)... WEST LAFAYETTE, Ind. ╤ A Smoky Mountain for...ate may play a role in how forest understories rec...research. , Despite heavy logging in portions of...of trillium plants on the secondary forest floor w...enkins, a Purdue assistant professor of forestry a...
Breaking Biology News(10 mins):Cigarette smoking increases colorectal cancer risk 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Study finds logging effects vary based on a forest's history, climate 2Service Outsourcing Opportunities in Medical Device Market worth US 2426 77 Billion by 2014 6193 1Service Outsourcing Opportunities in Medical Device Market worth US 2426 77 Billion by 2014 6193 2Service Outsourcing Opportunities in Medical Device Market worth US 2426 77 Billion by 2014 6193 3SciScout LLC Launches SciAnswers com a Science Based Questions and Answers 28Q 26amp 3BA 29 Site with a Social Networking Perspective 14806 1SciScout LLC Launches SciAnswers com a Science Based Questions and Answers 28Q 26amp 3BA 29 Site with a Social Networking Perspective 14806 2SciScout LLC Launches SciAnswers com a Science Based Questions and Answers 28Q 26amp 3BA 29 Site with a Social Networking Perspective 14806 3SciScout LLC Launches SciAnswers com a Science Based Questions and Answers 28Q 26amp 3BA 29 Site with a Social Networking Perspective 14806 4Stemedica President Invited To Lecture At The University Of Oxford 61211 1Stemedica President Invited To Lecture At The University Of Oxford 61211 2Stemedica President Invited To Lecture At The University Of Oxford 61211 3
...enome Research Institute (NHGRI), one of the Natio...veral new sequencing targets including the Norther...ing the stage for completing a quest to sequence t... from each of the major positions along the evolut...ial resource for researchers unraveling the geneti...
... global study has found all forms of tobacco expos...second hand smoke, increase the risk of heart atta...n Teo of the Michael G. DeGroote School of Medicin...ces in Hamilton, is published in this week,s issue...es from 52 countries, they calculated the risk of ...
...nnas contain 70% of the world,s plants and are cri...ernational project involving researchers from the ...the impact of global warming on these sensitive ar...t of a vicious cycle, where global warming causes ...t of carbon in the atmosphere, raising the earth,s...
Other Biology News:NHGRI announces latest sequencing targets 2NHGRI announces latest sequencing targets 3NHGRI announces latest sequencing targets 4NHGRI announces latest sequencing targets 5NHGRI announces latest sequencing targets 6Global study shows all tobacco bad for the heart 2Global study shows all tobacco bad for the heart 3The vicious cycle of rainforest destruction 2
(Date:12/2/2009)...alif., Dec. 2 Peregrine ...ted completion of patient enrollment in a dose con...atients with relapsed glioblastoma multiforme (GBM...a targeted monoclonal antibody linked to a radiois... for GBM. Cotara specifically targets cells at th...
(Date:12/2/2009)...D, The Netherlands, December 2 Pep...gy company focusing on protein mimicking,technolog...announced that it,has appointed Wim E.M. Mol, Ph.D...ol will be responsible for all of Pepscans corpora...gic direction of the company. He brings to,Pepscan...
(Date:12/2/2009)...ORE, Dec. 2 S*BIO Pte Ltd today an...inhibitor, SB1518, at The American Society of Hema...rleans. ,, Data will be presented on the clinic...of SB1518 detailing its safety, tolerability and p...dose levels ranging from 100 to 600 mg. These dose...
(Date:12/2/2009)... Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris ... global biopharmaceutical company focused on endoc...e U.S. Food and Drug Administration (FDA) has gran...Akt pathway inhibitor compound, perifosine (KRX-04...iple myeloma. Keryx Biopharmaceuticals, Inc. ("Ker...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3
...ilestone achieved bringing Enerkem one step closer...d biochemicals to commercially use waste, feeds...m Inc., a leading advanced biofuels and biochemica...rst commercial-scale plant located in Westbury, Qu...uction of its clean conditioned synthesis gas. , C...
...ucted by Novartis to evaluate safety and efficacy ...ination with ribavirin in patients with genotypes ... Human Genome Sciences, Inc. (Nasdaq: HGSI ) to...n a Phase 2b trial that will evaluate the safety a...) administered monthly in combination with ribavir...
...R, Jersey, January 12 , - Reflects Strong Int...f,World,s Leading IP Management Specialist and Leg...ld,s top intellectual property,( http://www.cpaglo... provider,of outsourced legal support services, ha...launch of a new brand worldwide. , Founded in ...
Other Biology Technology:Enerkem announces first commercial-scale biofuels and biochemicals plant is entering start-up phase 2Enerkem announces first commercial-scale biofuels and biochemicals plant is entering start-up phase 3Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 2Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 3Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 4Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 5CPA Global Marks 40th Anniversary With Launch of New Brand 2CPA Global Marks 40th Anniversary With Launch of New Brand 3
Epi-Grids Colony Grid Templates-24 Squares from EPICENTRE Biotechnologies
Mouse IgG3 EIA Kit from Assay Designs/Stressgen Bioreagents
...ains 200 g of lyophilized peptide derived from the...ds 380-402; GLTPSAWEASSLRSSRHSGLSHF. This peptid...s EP1 receptor polyclonal antibody (Catalog No. 10...ibody to block protein-antibody complex formation ...
Goat Anti-Mouse Ig + IgM Antibody, FITC Conjugated from Cayman Chemical
Biology Products: